Clinical Trial: A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)

U.S., May 10 -- ClinicalTrials.gov registry received information related to the study (NCT06963710) titled 'A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)' on April 22.

Brief Summary: This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection.

Study Start Date: May, 2025

Study Type: INTERVENTIONAL

Condition: Chronic Hepatitis B Infection

Intervention: DRUG: ALG-000184

300 mg tablet

DRUG: TDF

300 mg tablet

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Ali...